Drug Profile
REC 2282
Alternative Names: AR-42; NSC-D736012; OSU-HDAC42; REC-2282Latest Information Update: 04 May 2023
Price :
$50
*
At a glance
- Originator Ohio State University Research Foundation
- Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Recursion Pharmaceuticals; Virginia Commonwealth University
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Neurofibromatosis 2
- No development reported Acute myeloid leukaemia
- Discontinued Bladder cancer; Chronic lymphocytic leukaemia; Lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 04 May 2023 REC 2282 receives Orphan Drug status for Neurofibromatosis 2 in USA, prior to May 2203
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in human hepatocellular carcinoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2022 Phase-II/III clinical trials in Neurofibromatosis 2 (In adolescents, In adults, In children, In the elderly) in USA (PO) (NCT05130866)